H460 Cell Line Derived Xenograft
H460 CDX, a subcutaneous, large cell lung cancer xenograft tumor model functions as a tool for preclinical drug discovery, drug combination studies and the discovery of biomarkers. This model allows tumor cells to interact with their microenvironment, in contrast to studies performed on single layer, cultured cells. H460 cells are often used in cancer research to evaluate the effectiveness of new anti-cancer drugs and to investigate the molecular mechanisms underlying drug resistance. They have also been used as a model system to study the molecular biology of lung cancer and to identify potential therapeutic targets and biomarkers for this disease. Additionally, H460 cells have been used in studies investigating the effects of environmental toxins and other stressors on lung cancer development and progression.
The H460 xenograft model is an established human non-small cell lung cancer (NSCLC) model derived from the NCI-H460 cell line, which originates from a large cell lung carcinoma. It is widely used in preclinical oncology studies to evaluate the efficacy of anticancer therapeutics, including chemotherapy, targeted therapies, and immunotherapies. The model is characterized by its aggressive tumor growth, high proliferation rate, and robust tumor engraftment in immunocompromised mice, such as nude or SCID mice. Gene expression analysis of H460 tumors reveals high levels of KRAS and MYC, which are commonly associated with tumor progression and poor prognosis in lung cancer. The cell line exhibits significant expression of epithelial-mesenchymal transition (EMT)-associated markers, contributing to its invasive potential. Additionally, it expresses angiogenesis-related factors such as VEGF, supporting its use in studies targeting tumor vasculature. Genetically, H460 harbors key mutations that drive tumorigenesis. It has a KRAS Q61H mutation, which leads to constitutive activation of the RAS signaling pathway, promoting cell proliferation and survival. TP53 harbors a Y220C mutation, impairing its tumor suppressor function and contributing to genomic instability. Additionally, the model exhibits mutations in STK11, which affects metabolic regulation and enhances tumor aggressiveness. These molecular characteristics make the H460 xenograft model a valuable tool for investigating lung cancer biology and testing novel therapeutics targeting RAS-driven and TP53-mutant malignancies.
The H460 cell line (human lung) is used to create the CDX mouse model. H460 cells are notable for their high sensitivity to chemotherapeutic drugs such as cisplatin and etoposide, which makes them a valuable tool for evaluating the efficacy of new cancer treatments. Researchers also use H460 cells to investigate the molecular mechanisms underlying lung cancer development and progression, and to identify potential therapeutic targets and biomarkers of the disease.
| H460 | CDKN2A(del), PIK3CA(mut), KRAS(mut) |
| Origin | Lung |
| Disease | Carcinoma, large cell |
| Metastatic Models (Lung) | A549 |
| Non-Metastatic Models (Lung) | Calu-3, Calu-6, H1155, H460, LL/2, NCI-H1975, NCI-H226 |
Get Instant Quote for
H460 Xenograft Model
What we offer?
Our in vivo xenograft service department evaluates the efficacy of preclinical and clinical cancer therapeutics utilizing more than 50 validated immunocompromised xenograft mouse models. The value of utilizing our xenograft service department is highlighted by the ability to completely characterize the efficacy, dose regimen, dose levels and optimal combination ratios of lead compounds for cancer, obesity, diabetes, infections and immunology research.
During the design and execution of the xenograft study, our scientists will communicate with and assist the client’s decisions regarding these details:
- Study Group Formation: classification of mice by body weight, tumor size or other parameters
- Cancer Cell Line: use of in-house cell lines or utilization of customer-provided cell lines
- Tumor Implantation: intraperitoneal, subcutaneous, submuscular or intravenous
- Test Compound Administration: intraperitoneal, intravenous, tail vein, subcutaneous, topical, oral gavage, osmotic pumps or subcutaneous drug pellets
- Sample Collection: Tumors/tissues can be fixed in 10% NBF, frozen in liquid N2 or stabilized in RNAlater; blood chemistry analysis can be performed throughout the in-life portion of study
Vivarium
Our vivarium is designed such that it enables cost-effective and first-rate preclinical effectiveness testing services. All animal handling and maintenance is regulated following IACUC guidelines. Our facility consists of the following:
- IACUC-regulated and GLP-compliant
- Controlled, limited access lab areas
- Disposable cages
- Sterile food and water
- SPF (specific pathogen-free) animals to guarantee pathogens do not interfere with the experiment
- Established animal handling and micro-injection equipment systems, including an animal health observation program
- All studies follow pre-approved SOPs
Our staff understands that each proposed study design is unique and customized to the client’s needs. We also recognize the importance of the delivered results as being confidential, highly reproducible and that 100% of the intellectual property (IP) is owned by the client.
In order to receive a quote for your xenograft study, email us the specific details listed below in order to efficiently begin the study quote process:
- Cancer cell line(s) used in the study
- Number (n=) of animals in each study group
- Number of study groups and control groups
- Tumor implantation route
- Administration route of test compound
- Species of immunocompromised mouse (e.g. NOD/SCID, athymic Nude)
- Treatment and dose schedule
- Study endpoint and analysis (e.g. tumor growth delay, PK/PD, survival, toxicity, drug combinations)
- Samples collected: tumor and tissues to be collected, including storage condition (e.g. snap frozen, RNAlater, 10% NBF, nucleic acid isolation)